Richa Sharma/X
Sep 3, 2025, 12:48
Richa Sharma Shares ARCADIA Post-Hoc Findings: Apixaban Prevents Recurrent Stroke in ESUS Patients with LV Dysfunction
Richa Sharma, Associate Professor of Neurology at Yale School of Medicine, has shared a post on X:
“Lower risk of recurrent stroke among patients with ESUS and left ventricular dysfunction randomized to apixaban in the ARCADIA trial in our post-hoc analysis.”
Title: Lower risk of recurrent stroke among patients with ESUS and left ventricular dysfunction randomized to apixaban in the ARCADIA trial in our post-hoc analysis.
Authors: Richa Sharma, Dinesh Jillella, Cenai Zhang, Mitchell S.V. Elkind, Hooman Kamel, Marco R. Di Tullio, Richard A. Kronmal, Balaji Krishnaiah, Shadi Yaghi, W.T. Longstreth Jr, David Tirschwell, Alexander Merkler, Fadi Nahab

Read the full article here.
Find similar posts on Hemostasis Today.
-
Feb 2, 2026, 17:54Danny Gaskin: Nominations are Open for the BBTS Transfusion Practitioner Special Interest Group Award 2026
-
Feb 2, 2026, 17:44Important Webinar on Care for Patients with iTTP – ISTH
-
Feb 2, 2026, 17:21Tagreed Alkaltham: Some Risks Don’t Look Like Risks in Healthcare
-
Feb 2, 2026, 17:16Sifat Jubaira: Effect of Prolonged Tourniquet Application
-
Feb 2, 2026, 17:14Vivek Mahto: Understanding Deep Vein Thrombosis – Causes, Symptoms, and Prevention
-
Feb 2, 2026, 17:08Tareq Abadl: Heparin vs Warfarin
-
Feb 2, 2026, 17:07Mary Cushman: New Research on Aspirin Use in Pregnancy and Stroke Risk in Offspring
-
Feb 2, 2026, 16:52Aravind Palraj: Young Stroke is Never Just Stroke
-
Feb 2, 2026, 16:48Seyed Mohsen Jahromi Moghadam: Antithrombotic Therapy After Transcatheter Structural Heart Interventions